LM-2417

LM-2417 is an investigational monoclonal antibody developed by LaNova Medicines for the treatment of advanced solid tumors. It is currently being evaluated in a Phase 1/2 clinical trial to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity as both a single agent and in combination with other antitumor agents. The precise molecular target and mechanism of action have not been publicly disclosed; however, some sources suggest it may be a PARP inhibitor, though this has not been confirmed. The drug utilizes LaNova's multiple transmembrane protein antibody discovery platform[1][3][5].